In this study 15 years of data from a single hospital were assessed to look at the outcomes of people who had had surgery for localised renal cell carcinoma (RCC). Of the 1895 people who were assessed, 30 (1.6%) had a single local recurrence of their cancer without distant spread (metastases). In total, 26 of […]
Percutaneous microwave ablation uses thin needle-like electrodes that are passed through the skin (percutaneous) into the tumour to kill the cancer cells with microwaves. This is usually done under the guidance of ultrasound imaging. During this observational study the short- and long-term outcomes of 113 patients who had microwave ablation for small renal masses (stage […]
A recent study published in Blood has suggested that cancer patients who are being treated with immunotherapy, in particular immune checkpoint inhibitors are at high risk for blood clots (thromboembolism), especially blood clots in veins (venous thromboembolism). Although, the study does not show a causal link between immune checkpoint inhibitor therapy and blood clots. The […]
Three phase III clinical trials (Keynote 426, Checkmate 9ER and Checkmate 214) assessing first-line treatment with immunotherapy in metastatic renal cell carcinoma (RCC) compared to sunitinib were analysed for patients who had prior nephrectomy compared to those who did not. Patients who had prior nephrectomy had a longer time before the immunotherapy stopped working and […]
Despite the advances in first-line treatments for metastatic renal cell carcinoma (RCC) over the past few years, new treatments are on the horizon. In a presentation at the European International Kidney Cancer (EIKC) 2021 Virtual Annual Meeting, Dr Hans Hammers from University of Texas Southwestern Medical Center in the USA discussed future treatments for metastatic […]
Dr Thomas Powles from St Barts Hospital, London spoke about the work looking for tissue-based biomarkers for renal cell carcinoma (RCC) for potential use in the clinic at the European International Kidney Cancer Symposium (EIKC) 2021 Virtual Meeting. To date, the only biomarker that is used is one to predict survival (prognosis) based on the […]
The increase in the number of first-line treatments for metastatic renal cell carcinoma (RCC) over the past 3 years has had meaningful effects on the choice of second-line treatments. Dr Camillo Porta from the University of Pavia in Italy discussed the selection of second-line and later treatments in a presentation at the European International Kidney […]
The use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has increased significantly over the past 3 years. However, there are now a number of potential first-line treatments, and choosing the most suitable treatment for each individual patient can be difficult. In a presentation at the European International Kidney Cancer […]
There is very little information on the effectiveness of sunitinib (a vascular endothelial growth factor (VEGF) inhibitor) as a second-line treatment after first-line treatment with immunotherapy for patients with metastatic renal cell carcinoma (RCC). A study published in Clinical Genitourinary Cancer last month looked at 102 patients in a real-world setting who were treated with […]
A recent study published in Journal of the National Comprehensive Cancer Network suggests that brain scans should be considered in most patients with metastatic kidney cancer. 1,689 people with metastatic renal cell carcinoma (RCC) had MRI brain scans for entry into clinical trials. Of these, 4% had brain metastases that did not show any symptoms. […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
